bluebird bio (BLUE) Splitting Could Increase an M&A Premium for Each Entity - Stifel
Tweet Send to a Friend
Stifel analyst Benjamin Burnett reiterated a Hold rating and $48.00 price target on bluebird bio (NASDAQ: BLUE) but believes the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
